LENSAR-Alcon Merger Terminated After FTC Block Threat; Stock Plunges
LENSAR and Alcon have mutually terminated their merger after the Federal Trade Commission threatened to block the deal.
NOTRELOAD AI
Rhythm Announces EMANATE Topline Results: Primary Endpoints Missed, But Next-Gen Drugs Get a Boost
Rhythm Pharmaceuticals announced that setmelanotide missed its primary endpoints in the Phase 3 EMANATE trial. Post-hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 patients.
Why HSBC Just Turned Bearish on Eli Lilly: Price Wars and Overhyped Weight-Loss Expectations
HSBC downgraded Eli Lilly to Reduce from Hold, cutting its price target to $850 from $1,070. The analyst cites an overhyped $150B+ obesity market, rising price competition, and expected cuts in 2026.
Tandem Diabetes Stock Gets a Boost: Analyst Upgrade Signals 50%+ Upside Potential
Piper Sandler upgrades Tandem Diabetes to Overweight from Neutral, raises PT to $33 from $21. Mobi pump, pharmacy pricing, and international growth drive revenue upside.
AEye Joins NVIDIA’s Halos AI Safety Lab to Advance Safer Self-Driving and Physical AI Solutions
AEye shares jump after joining NVIDIA’s first accredited Halos AI Safety Lab. Partnership boosts safety-certified long-range Apollo lidar for autonomous vehicles and physical AI.
Nvidia Supercharges Uber & Lyft: Robotaxis Hit LA and SF in 2027, Global Expansion by 2028
Uber and Lyft stocks rise after Nvidia announces expanded partnerships at GTC 2026, with Uber planning Level-4 robotaxis in Los Angeles and San Francisco in 2027, scaling to 28 global cities by 2028. Lyft boosts AI for rides and mapping.